Ibrutinib (Treatment B)
Sponsors
Janssen Research & Development, LLC
Conditions
Healthy
Phase 1
A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
CompletedNCT02390609
Start: 2015-03-31End: 2015-11-30Updated: 2015-12-23
Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules
CompletedNCT02841150
Start: 2016-06-30End: 2016-08-31Updated: 2018-03-29